Neuromodulation Devices Market By Type (Invasive and Non-Invasive), By Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), By Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), By End User (Hospitals, Specialty Clinics, and Others), By Geography is expected to grow at a static CAGR Forecast till 2027 due to Advances in Product Portfolio and Burgeoning Neurological Disorder Prevalence among the aging population
Global Neuromodulation Devices Market was valued at USD 5.71 billion in 2021, growing at a CAGR of 8.95% during the forecast period from 2022 to 2027, to reach USD 9.56 billion. The demand for neuromodulation devices is primarily motivated by the increasing prevalence of neurological disorder coupled with rising aging population, expansion of the devices to other chronic indications and target application, technological advancement in the product portfolio, rising government initiative to raise awareness among patient regarding neurological disorders, among others.
Neurological disorders are the diseases that affect the central and peripheral nervous system which primarily include brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles. According to WHO 2021 report, more than 50 million people have epilepsy worldwide and it is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year. The report also state that Alzheimer's disease is the most common cause of dementia and may contribute to 60-70% of cases. Further, the prevalence of migraine is more than 10% worldwide.
Neuromodulation is a technique that directly acts on nerves. It changes (or modulates) nerve activity by delivering electrical stimulation directly to the target area. Neuromodulation devices involve applying electrodes to the brain, spinal cord, or peripheral nerves to treat or reduce the symptom of various neurological disorders such as epilepsy, migraine, Parkinson's disease, among others. Therefore rising prevalence of various neurological disorder across the globe could be a potential factor leading to the growth of the global neuromodulation devices market.
Moreover, neuromodulation devices treat almost all diseases or symptoms, from headaches to tremors, spinal cord injuries and urinary incontinence, and others. With such a wide range of treatments and significant continuous improvements in biotechnology, it is not surprising that neuromodulation is positioned as a high-growth industry during the forecasted period. In addition to treating chronic pain, there are many neuromodulation applications, such as deep brain stimulation (DBS) treatment for Parkinson's disease, sacral nerve stimulation for pelvic diseases and urinary incontinence. For instance, ENTERRA II NEUROSTIMULATOR by Medtronic is a gastric neurostimulator that generates mild electrical pulses for gastric electrical stimulation to treat chronic, intractable nausea and vomiting due to gastroparesis.
Therefore, expansion device usage to other chronic indications and targeted application is also anticipated to propel the global neuromodulation devices market. However, certain factors such as high cost of these devices and lower rate of diagnosis and treatment is likely to impede the growth of the neuromodulation devices market.
Neuromodulation Devices Market by Type (Invasive And Non-Invasive), by Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, And Others), by Application (Pain Management, Neurological Disorder, Respiratory Disorders, And Others), by End User (Hospitals, Specialty Clinics, And Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In Neuromodulation Devices product segment, spinal cord stimulators holds the significant market during the forecasted period. This is owing to the growing patient population suffering with chronic pain, failed back syndrome, and complex regional pain syndrome (CRPS). For instance, according to CDC 2020 data, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities (referred to as high impact chronic pain) and both increased with age and were highest among adults aged 65 and over.
Moreover, recent product launches of technologically advanced spinal cord stimulators with rechargeable batteries and wireless remote technique also contribute to the segmental growth. For instance, in 2020, Boston Scientific Corporation launched the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems in Europe. The portfolio consist of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.
In addition, emerging guidelines from government for spinal cord stimulation therapy for the treatment of chronic pain and other indications is also anticipated to augment the market. For instance, in January 2019, National Institute for Health and Care Excellence (NICE) published guidelines and recommendation for Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Hence, all the mentioned factors are likely to fuel the segmental growth of Neuromodulation Devices market during the forecasted period.
North America is expected to dominate the overall Neuromodulation Devices market during the forecast period. This domination is due to the increased healthcare expenditure along with the presence of well-developed and advanced healthcare system in the region. Moreover higher diagnosis and treatment rate and adequate reimbursement policies are the driving factors.
Further, In the United States, presence of key market players such as Abbott, Boston Scientific Corporation, Medtronic, among others is likely to boost the market. Also, growing prevalence of neurological disorders such as epilepsy, migraine, treatment resistant depressive order is also expected to bolster the market. For instance, as per the CDC 2020 report, in 2015, 1.2% of the US population had active epilepsy which was about 3.4 million people with epilepsy nationwide: 3 million adults and 470,000 children. Thus, rising active epilepsy among other neurological disorder could be a significant factor for Neuromodulation Devices market growth.
Moreover, increase in product approval by FDA is also a driving factor for the neuromodulation devices in the region. For instance, in June 2020, Medtronic received Food and Drug Administration (FDA) approval for the Percept™ PC Deep Brain Stimulation (DBS) system. BrainSense™ technology makes Percept the first and only DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson's disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder (OCD).
Thus, aforementioned factors are likely to upsurge the market for Neuromodulation Devices in the region.
Furthermore, Asia-Pacific region has the future potential growth for the Global Neuromodulation Devices. This is due to the improving healthcare infrastructure, increasing per capita healthcare expenditure, rising disposable income, rising old age population, among others. Additionally, recent product development activities among key manufacturers for the expansion of product portfolio in APAC region will also boost the market. For instance, in 2021, Neurolief Ltd., a neurotechnology innovator entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan.
Some of the key market players operating in the Neuromodulation Devices market includes Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others.
What are Neuromodulation Devices?
Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.
What is the market for Global Neuromodulation Devices?
Global Neuromodulation Devices Market was valued at USD 5.71 billion in 2021, growing at a CAGR of 8.95% during the forecast period from 2022 to 2027, to reach USD 9.56 billion by 2027.
What are the drivers for Global Neuromodulation Devices?
The major factors driving the demand for Neuromodulation Devices are growing prevalence of neurological disorder coupled with rising geriatric population, expanding device application in various other indication, and launch of technically advanced products in the market.
What are the key players operating in Global Neuromodulation Devices?
Some of the key market players operating in the Neuromodulation Devices market includes Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others
What regions has the highest share in Neuromodulation Devices market?
North America is anticipated to dominate the overall Neuromodulation Devices market during the forecast period, 2022-2027 due to the increased healthcare expenditure along with the presence of well-developed and advanced healthcare system in the region. Furthermore, rising diagnosis and treatment rate and adequate reimbursement policies also contribute to highest regional share.
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.
Global Neuromodulation Devices Market was valued at USD 5.71 billion in 2021, growing at a CAGR of 8.95% during the forecast period from 2022 to 2027, to reach USD 9.56 billion. The demand for neuromodulation devices is primarily motivated by the increasing prevalence of neurological disorder coupled with rising aging population, expansion of the devices to other chronic indications and target application, technological advancement in the product portfolio, rising government initiative to raise awareness among patient regarding neurological disorders, among others.
Neuromodulation Devices Market Dynamics:
Neurological disorders are the diseases that affect the central and peripheral nervous system which primarily include brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles. According to WHO 2021 report, more than 50 million people have epilepsy worldwide and it is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year. The report also state that Alzheimer's disease is the most common cause of dementia and may contribute to 60-70% of cases. Further, the prevalence of migraine is more than 10% worldwide.
Neuromodulation is a technique that directly acts on nerves. It changes (or modulates) nerve activity by delivering electrical stimulation directly to the target area. Neuromodulation devices involve applying electrodes to the brain, spinal cord, or peripheral nerves to treat or reduce the symptom of various neurological disorders such as epilepsy, migraine, Parkinson's disease, among others. Therefore rising prevalence of various neurological disorder across the globe could be a potential factor leading to the growth of the global neuromodulation devices market.
Moreover, neuromodulation devices treat almost all diseases or symptoms, from headaches to tremors, spinal cord injuries and urinary incontinence, and others. With such a wide range of treatments and significant continuous improvements in biotechnology, it is not surprising that neuromodulation is positioned as a high-growth industry during the forecasted period. In addition to treating chronic pain, there are many neuromodulation applications, such as deep brain stimulation (DBS) treatment for Parkinson's disease, sacral nerve stimulation for pelvic diseases and urinary incontinence. For instance, ENTERRA II NEUROSTIMULATOR by Medtronic is a gastric neurostimulator that generates mild electrical pulses for gastric electrical stimulation to treat chronic, intractable nausea and vomiting due to gastroparesis.
Therefore, expansion device usage to other chronic indications and targeted application is also anticipated to propel the global neuromodulation devices market. However, certain factors such as high cost of these devices and lower rate of diagnosis and treatment is likely to impede the growth of the neuromodulation devices market.
Neuromodulation Devices Market Segment Analysis:
Neuromodulation Devices Market by Type (Invasive And Non-Invasive), by Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, And Others), by Application (Pain Management, Neurological Disorder, Respiratory Disorders, And Others), by End User (Hospitals, Specialty Clinics, And Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In Neuromodulation Devices product segment, spinal cord stimulators holds the significant market during the forecasted period. This is owing to the growing patient population suffering with chronic pain, failed back syndrome, and complex regional pain syndrome (CRPS). For instance, according to CDC 2020 data, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities (referred to as high impact chronic pain) and both increased with age and were highest among adults aged 65 and over.
Moreover, recent product launches of technologically advanced spinal cord stimulators with rechargeable batteries and wireless remote technique also contribute to the segmental growth. For instance, in 2020, Boston Scientific Corporation launched the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems in Europe. The portfolio consist of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.
In addition, emerging guidelines from government for spinal cord stimulation therapy for the treatment of chronic pain and other indications is also anticipated to augment the market. For instance, in January 2019, National Institute for Health and Care Excellence (NICE) published guidelines and recommendation for Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Hence, all the mentioned factors are likely to fuel the segmental growth of Neuromodulation Devices market during the forecasted period.
North America is expected to dominate the overall Neuromodulation Devices Market:
North America is expected to dominate the overall Neuromodulation Devices market during the forecast period. This domination is due to the increased healthcare expenditure along with the presence of well-developed and advanced healthcare system in the region. Moreover higher diagnosis and treatment rate and adequate reimbursement policies are the driving factors.
Further, In the United States, presence of key market players such as Abbott, Boston Scientific Corporation, Medtronic, among others is likely to boost the market. Also, growing prevalence of neurological disorders such as epilepsy, migraine, treatment resistant depressive order is also expected to bolster the market. For instance, as per the CDC 2020 report, in 2015, 1.2% of the US population had active epilepsy which was about 3.4 million people with epilepsy nationwide: 3 million adults and 470,000 children. Thus, rising active epilepsy among other neurological disorder could be a significant factor for Neuromodulation Devices market growth.
Moreover, increase in product approval by FDA is also a driving factor for the neuromodulation devices in the region. For instance, in June 2020, Medtronic received Food and Drug Administration (FDA) approval for the Percept™ PC Deep Brain Stimulation (DBS) system. BrainSense™ technology makes Percept the first and only DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson's disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder (OCD).
Thus, aforementioned factors are likely to upsurge the market for Neuromodulation Devices in the region.
Furthermore, Asia-Pacific region has the future potential growth for the Global Neuromodulation Devices. This is due to the improving healthcare infrastructure, increasing per capita healthcare expenditure, rising disposable income, rising old age population, among others. Additionally, recent product development activities among key manufacturers for the expansion of product portfolio in APAC region will also boost the market. For instance, in 2021, Neurolief Ltd., a neurotechnology innovator entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan.
Neuromodulation Devices Market Key Players:
Some of the key market players operating in the Neuromodulation Devices market includes Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others.
Recent Developmental Activities in Neuromodulation Devices Market:
- In March 2021, Axonics Modulation Technologies, Inc. entered into a strategic alliance with Micro Systems Technologies (MST) for the manufacture of a non-rechargeable implantable sacral neuromodulation device.
- In March 2021, Helius Medical received the US FDA approval for Portable Neuromodulation Stimulator approval for short-term treatment of gait deficit due to multiple sclerosis.
- In January 2021, Boston Scientific Corporation received FDA approval for its fourth generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson's disease.
- In January 2020, Abbott received expanded indication from the US FDA For directional deep brain stimulation system to treat Parkinson's disease.
- Market size analysis for current market size (2021), and market forecast for 5 years (2022-2027)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Neuromodulation Devices market.
- Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
- Key companies dominating the Global Neuromodulation Devices Market.
- Various opportunities available for the other competitor in the Neuromodulation Devices Market space.
- What are the top performing segments in 2021? How these segments will perform in 2027.
- Which is the top-performing regions and countries in the current market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for Neuromodulation Devices market growth in the coming future?
Target Audience who can be benefited from Neuromodulation Devices Market Report Study
- Neuromodulation Devices providers
- Research organizations and consulting companies
- Neuromodulation Devices-related organization, association, forum, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders in Neuromodulation Devices
- Various End-users who want to know more about the Neuromodulation Devices Market and latest technological developments in the Neuromodulation Devices market.
Frequently Asked Questions for Neuromodulation Devices Market:
What are Neuromodulation Devices?
Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.
What is the market for Global Neuromodulation Devices?
Global Neuromodulation Devices Market was valued at USD 5.71 billion in 2021, growing at a CAGR of 8.95% during the forecast period from 2022 to 2027, to reach USD 9.56 billion by 2027.
What are the drivers for Global Neuromodulation Devices?
The major factors driving the demand for Neuromodulation Devices are growing prevalence of neurological disorder coupled with rising geriatric population, expanding device application in various other indication, and launch of technically advanced products in the market.
What are the key players operating in Global Neuromodulation Devices?
Some of the key market players operating in the Neuromodulation Devices market includes Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others
What regions has the highest share in Neuromodulation Devices market?
North America is anticipated to dominate the overall Neuromodulation Devices market during the forecast period, 2022-2027 due to the increased healthcare expenditure along with the presence of well-developed and advanced healthcare system in the region. Furthermore, rising diagnosis and treatment rate and adequate reimbursement policies also contribute to highest regional share.
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.
Table of Contents
1. Neuromodulation Devices Report Introduction2. Neuromodulation Devices Executive summary
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. Regulatory and Patent Analysis
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 U.K.
3.3 Japan
4 Neuromodulation Devices Market Key factors analysis
4.1 Neuromodulation Devices Market Drivers
4.1.1 Increasing prevalence of neurological disorder coupled with rising aging population
4.1.2 Expansion of the devices to other chronic indications and target application
4.1.3 Technological advancement in the product portfolio
4.1.4 Rising government initiative to raise awareness among patient regarding neurological disorders
4.2 Neuromodulation Devices Market Restraints and Challenges
4.2.1 High cost of the devices and procedure
4.2.2 Complex regulatory approval scenario
4.3 Neuromodulation Devices Market Opportunities
4.3.1 Growing demand for non-invasive devices
4.3.2 Market growth opportunities in developing nations
5 Neuromodulation Devices Porter's Five Forces Analysis
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6 COVID-19 Impact Analysis on Neuromodulation Devices Market
7. Neuromodulation Devices Market layout
7.1 By Type
7.1.1 Invasive
7.1.2 Non-invasive
7.2 By Product Type
7.2.1 Spinal Cord Stimulators
7.2.2 Vagus Nerve Stimulators
7.2.3 Deep Brain Stimulators
7.2.4 Sacral Nerve Stimulators
7.2.5 Transcranial Magnetic Stimulators
7.2.6 Others
7.3 By Application
7.3.1 Pain Management
7.3.2 Neurological disorder
7.3.3 Respiratory disorder
7.3.4 Others
7.4 By End user
7.4.1 Hospitals
7.4.2 Specialty Clinics
7.4.3 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 North America Neuromodulation Devices Market, by Type
7.5.1.2 North America Neuromodulation Devices Market, by Product Type
7.5.1.3 North America Neuromodulation Devices Market, by Application
7.5.1.4 North America Neuromodulation Devices Market, by End User
7.5.1.5 North America Neuromodulation Devices Market, by Country
7.5.1.5.1 United States
7.5.1.5.2 Canada
7.5.1.5.3 Mexico
7.5.2 Europe
7.5.2.1 Europe Neuromodulation Devices Market, by Type
7.5.2.2 Europe Neuromodulation Devices Market, by Product Type
7.5.2.3 Europe Neuromodulation Devices Market, by Application
7.5.2.4 Europe Neuromodulation Devices Market, by End User
7.5.2.5 Europe Neuromodulation Devices Market, by Country
7.5.2.5.1 France
7.5.2.5.2 Germany
7.5.2.5.3 United Kingdom
7.5.2.5.4 Italy
7.5.2.5.5 Spain
7.5.2.5.6 Russia
7.5.2.5.7 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 Asia-Pacific Neuromodulation Devices Market, by Type
7.5.3.2 Asia-Pacific Neuromodulation Devices Market, by Product Type
7.5.3.3 Asia-Pacific Neuromodulation Devices Market, by Application
7.5.3.4 Asia-Pacific Neuromodulation Devices Market, by End User
7.5.3.5 Asia-Pacific Neuromodulation Devices Market, by Country
7.5.3.5.1 China
7.5.3.5.2 Japan
7.5.3.5.3 India
7.5.3.5.4 Australia
7.5.3.5.5 South Korea
7.5.3.5.6 Rest of Asia Pacific
7.5.4 Rest of the World (RoW)
7.5.4.1 RoW Neuromodulation Devices Market, by Type
7.5.4.2 RoW Neuromodulation Devices Market, by Product Type
7.5.4.3 RoW Neuromodulation Devices Market, by Application
7.5.4.4 RoW Neuromodulation Devices Market, by End User
7.5.4.5 RoW Neuromodulation Devices Market, by Region
7.5.4.5.1 Middle East
7.5.4.5.2 Africa
7.5.4.5.3 South America
8. Neuromodulation Devices Global Company Share Analysis - Key 3-5 Companies
9. Neuromodulation Devices Company and Product Profiles
9.1 Medtronic
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 Boston Scientific Corporation
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 Abbott
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 LivaNova
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 NeuroSigma
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 NEVRO CORP.
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 Synapse Biomedical Inc.
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 NeuroPace, Inc.
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 Bioventus
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 Soterix Medical Inc.
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 Helius Medical Technologies
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Axonics, Inc.
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 MicroTransponder Inc.
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 electroCore, Inc.
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL Views
12. Publisher Capabilities
13. Disclaimer
14. About the PublisherList of Tables
Table 1 Competitive Analysis
Table 2 COVID-19 Impact Analysis on Neuromodulation Devices Market Analysis
Table 3 Neuromodulation Devices Market Analysis in Global (2019-2027)
Table 4 Neuromodulation Devices Market Analysis in Global by Type (2019-2027)
Table 5 Neuromodulation Devices Market Analysis in Global by Product (2019-2027)
Table 6 Neuromodulation Devices Market Analysis in Global by Application (2019-2027)
Table 7 Neuromodulation Devices Market Analysis in Global by End User (2019-2027)
Table 8 Neuromodulation Devices Market Analysis in Global by Geography (2019-2027)
Table 9 Neuromodulation Devices Market Analysis in North America (2019-2027)
Table 10 Neuromodulation Devices Market Analysis in North America by Type (2019-2027)
Table 11 Neuromodulation Devices Market Analysis in North America by Product (2019-2027)
Table 12 Neuromodulation Devices Market Analysis in North America by Application (2019-2027)
Table 13 Neuromodulation Devices Market Analysis in North America by End User (2019-2027)
Table 14 Neuromodulation Devices Market Analysis in North America by Country (2019-2027)
Table 15 Neuromodulation Devices Market Analysis in the US (2019-2027)
Table 16 Neuromodulation Devices Market Analysis in Canada (2019-2027)
Table 17 Neuromodulation Devices Market Analysis in Mexico (2019-2027)
Table 18 Neuromodulation Devices Market Analysis in Europe (2019-2027)
Table 19 Neuromodulation Devices Market Analysis in Europe by Type (2019-2027)
Table 20 Neuromodulation Devices Market Analysis in Europe by Product (2019-2027)
Table 21 Neuromodulation Devices Market Analysis in Europe by Application (2019-2027)
Table 22 Neuromodulation Devices Market Analysis in Europe by End User (2019-2027)
Table 23 Neuromodulation Devices Market Analysis in Europe by Country (2019-2027)
Table 24 Neuromodulation Devices Market Analysis in France (2019-2027)
Table 25 Neuromodulation Devices Market Analysis in Germany (2019-2027)
Table 26 Neuromodulation Devices Market Analysis in the UK (2019-2027)
Table 27 Neuromodulation Devices Market Analysis in Italy (2019-2027)
Table 28 Neuromodulation Devices Market Analysis in Spain (2019-2027)
Table 29 Neuromodulation Devices Market Analysis in Russia (2019-2027)
Table 30 Neuromodulation Devices Market Analysis in Rest of Europe (2019-2027)
Table 31 Neuromodulation Devices Market Analysis in Asia-Pacific (2019-2027)
Table 32 Neuromodulation Devices Market Analysis in Asia-Pacific by Type (2019-2027)
Table 33 Neuromodulation Devices Market Analysis in Asia-Pacific by Product (2019-2027)
Table 34 Neuromodulation Devices Market Analysis in Asia-Pacific by Application (2019-2027)
Table 35 Neuromodulation Devices Market Analysis in Asia-Pacific by End User (2019-2027)
Table 36 Neuromodulation Devices Market Analysis in Asia-Pacific by Country (2019-2027)
Table 37 Neuromodulation Devices Market Analysis in China (2019-2027)
Table 38 Neuromodulation Devices Market Analysis in Japan (2019-2027)
Table 39 Neuromodulation Devices Market Analysis in India (2019-2027)
Table 40 Neuromodulation Devices Market Analysis in Australia (2019-2027)
Table 41 Neuromodulation Devices Market Analysis in South Korea (2019-2027)
Table 42 Neuromodulation Devices Market Analysis in Rest of Asia-Pacific (2019-2027)
Table 43 Neuromodulation Devices Market Analysis in Rest of World (2019-2027)
Table 44 Neuromodulation Devices Market Analysis in Rest of World by Type (2019-2027)
Table 45 Neuromodulation Devices Market Analysis in Rest of World by Product (2019-2027)
Table 46 Neuromodulation Devices Market Analysis in Rest of World by Application (2019-2027)
Table 47 Neuromodulation Devices Market Analysis in Rest of World by End User (2019-2027)
Table 48 Neuromodulation Devices Market Analysis in Rest of World by Country (2019-2027)
Table 49 Neuromodulation Devices Market Analysis in Middle East (2019-2027)
Table 50 Neuromodulation Devices Market Analysis in Africa (2019-2027)
Table 51 Neuromodulation Devices Market Analysis in South America (2019-2027)List of Figures
Figure 1 Competitive Analysis
Figure 2 COVID-19 Impact Analysis on Neuromodulation Devices Market Analysis
Figure 3 Neuromodulation Devices Market Analysis in Global (2019-2027)
Figure 4 Neuromodulation Devices Market Analysis in Global by Type (2019-2027)
Figure 5 Neuromodulation Devices Market Analysis in Global by Product (2019-2027)
Figure 6 Neuromodulation Devices Market Analysis in Global by Application (2019-2027)
Figure 7 Neuromodulation Devices Market Analysis in Global by End User (2019-2027)
Figure 8 Neuromodulation Devices Market Analysis in Global by Geography (2019-2027)
Figure 9 Neuromodulation Devices Market Analysis in North America (2019-2027)
Figure 10 Neuromodulation Devices Market Analysis in North America by Type (2019-2027)
Figure 11 Neuromodulation Devices Market Analysis in North America by Product (2019-2027)
Figure 12 Neuromodulation Devices Market Analysis in North America by Application (2019-2027)
Figure 13 Neuromodulation Devices Market Analysis in North America by End User (2019-2027)
Figure 14 Neuromodulation Devices Market Analysis in North America by Country (2019-2027)
Figure 15 Neuromodulation Devices Market Analysis in the US (2019-2027)
Figure 16 Neuromodulation Devices Market Analysis in Canada (2019-2027)
Figure 17 Neuromodulation Devices Market Analysis in Mexico (2019-2027)
Figure 18 Neuromodulation Devices Market Analysis in Europe (2019-2027)
Figure 19 Neuromodulation Devices Market Analysis in Europe by Type (2019-2027)
Figure 20 Neuromodulation Devices Market Analysis in Europe by Product (2019-2027)
Figure 21 Neuromodulation Devices Market Analysis in Europe by Application (2019-2027)
Figure 22 Neuromodulation Devices Market Analysis in Europe by End User (2019-2027)
Figure 23 Neuromodulation Devices Market Analysis in Europe by Country (2019-2027)
Figure 24 Neuromodulation Devices Market Analysis in France (2019-2027)
Figure 25 Neuromodulation Devices Market Analysis in Germany (2019-2027)
Figure 26 Neuromodulation Devices Market Analysis in the UK (2019-2027)
Figure 27 Neuromodulation Devices Market Analysis in Italy (2019-2027)
Figure 28 Neuromodulation Devices Market Analysis in Spain (2019-2027)
Figure 29 Neuromodulation Devices Market Analysis in Russia (2019-2027)
Figure 30 Neuromodulation Devices Market Analysis in Rest of Europe (2019-2027)
Figure 31 Neuromodulation Devices Market Analysis in Asia-Pacific (2019-2027)
Figure 32 Neuromodulation Devices Market Analysis in Asia-Pacific by Type (2019-2027)
Figure 33 Neuromodulation Devices Market Analysis in Asia-Pacific by Product (2019-2027)
Figure 34 Neuromodulation Devices Market Analysis in Asia-Pacific by Application (2019-2027)
Figure 35 Neuromodulation Devices Market Analysis in Asia-Pacific by End User (2019-2027)
Figure 36 Neuromodulation Devices Market Analysis in Asia-Pacific by Country (2019-2027)
Figure 37 Neuromodulation Devices Market Analysis in China (2019-2027)
Figure 38 Neuromodulation Devices Market Analysis in Japan (2019-2027)
Figure 39 Neuromodulation Devices Market Analysis in India (2019-2027)
Figure 40 Neuromodulation Devices Market Analysis in Australia (2019-2027)
Figure 41 Neuromodulation Devices Market Analysis in South Korea (2019-2027)
Figure 42 Neuromodulation Devices Market Analysis in Rest of Asia-Pacific (2019-2027)
Figure 43 Neuromodulation Devices Market Analysis in Rest of World (2019-2027)
Figure 44 Neuromodulation Devices Market Analysis in Rest of World by Type (2019-2027)
Figure 45 Neuromodulation Devices Market Analysis in Rest of World by Product (2019-2027)
Figure 46 Neuromodulation Devices Market Analysis in Rest of World by Application (2019-2027)
Figure 47 Neuromodulation Devices Market Analysis in Rest of World by End User (2019-2027)
Figure 48 Neuromodulation Devices Market Analysis in Rest of World by Country (2019-2027)
Figure 49 Neuromodulation Devices Market Analysis in Middle East (2019-2027)
Figure 50 Neuromodulation Devices Market Analysis in Africa (2019-2027)
Figure 51 Neuromodulation Devices Market Analysis in South America (2019-2027)
Figure 52 Market Drivers
Figure 53 Market Barriers
Figure 54 Market Opportunities
Figure 55 PORTER's Five Force Analysis
